Vanderbilt-Ingram Cancer Center

The VICC.ORG Investigator Directory

Robbert Slebos, Ph.D., M.H.S.

See also:

• Thoracic/Head and Neck Cancer Research Program
• Cancer Biology
• BRET: Biomedical Research Education & Training Faculty Listing

Research Assistant Professor of Cancer Biology and Otolaryngology
VICC Member
Researcher

Contact Information:

Vanderbilt University Medical Center
654 Preston Research Building, 2220 Pierce Avenue
Nashville , TN 37232-6838
615-936-2806
Fax: 615-936-2805

Research Specialty:

Translational research using shotgun proteomics for the detection of biomarkers of early detection, response prediction and prognosis of colorectal cancer and head and neck cancer.

Publications:

• Li, M, Gray, W, Zhang, H, Chung, CH, Billheimer, D, Yarbrough, WG, Liebler, DC, Shyr, Y, Slebos, RJ Comparative shotgun proteomics using spectral count data and quasi-likelihood modeling. J Proteome Res, 9(8), 4295-305, 2010.
• Lin, D, Li, J, Slebos, RJ, Liebler, DC Cysteinyl peptide capture for shotgun proteomics: global assessment of chemoselective fractionation. J Proteome Res, 9(10), 5461-72, 2010.
• Tu, C, Rudnick, PA, Martinez, MY, Cheek, KL, Stein, SE, Slebos, RJ, Liebler, DC Depletion of abundant plasma proteins and limitations of plasma proteomics. J Proteome Res, 9(10), 4982-91, 2010.
• Chung, CH, Aulino, J, Muldowney, NJ, Hatakeyama, H, Baumann, J, Burkey, B, Netterville, J, Sinard, R, Yarbrough, WG, Cmelak, AJ, Slebos, RJ, Shyr, Y, Parker, J, Gilbert, J, Murphy, BA Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol, 21(4), 864-70, 2010.
• Hatakeyama, H, Cheng, H, Wirth, P, Counsell, A, Marcrom, SR, Wood, CB, Pohlmann, PR, Gilbert, J, Murphy, B, Yarbrough, WG, Wheeler, DL, Harari, PM, Guo, Y, Shyr, Y, Slebos, RJ, Chung, CH Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One, 5(9), e12702, 2010.
• Dasari, S, Chambers, MC, Slebos, RJ, Zimmerman, LJ, Ham, AJ, Tabb, DL TagRecon: high-throughput mutation identification through sequence tagging. J Proteome Res, 9(4), 1716-26, 2010.
• Fiske, WH, Tanksley, J, Nam, KT, Goldenring, JR, Slebos, RJ, Liebler, DC, Abtahi, AM, La Fleur, B, Ayers, GD, Lind, CD, Washington, MK, Coffey, RJ Efficacy of cetuximab in the treatment of Menetrier''s disease. Sci Transl Med, 1(8), 8ra18, 2009.
• Sprung, RW, Brock, JW, Tanksley, JP, Li, M, Washington, MK, Slebos, RJ, Liebler, DC Equivalence of protein inventories obtained from formalin-fixed paraffin-embedded and frozen tissue in multidimensional liquid chromatography-tandem mass spectrometry shotgun proteomic analysis. Mol Cell Proteomics, 8(8), 1988-98, 2009.
• Baumann, JL, Cohen, S, Evjen, AN, Law, JH, Vadivelu, S, Attia, A, Schindler, JS, Chung, CH, Wirth, PS, Meijer, CJ, Snijders, PJ, Yarbrough, WG, Slebos, RJ Human papillomavirus in early laryngeal carcinoma. Laryngoscope, 119(8), 1531-7, 2009.
• Chung, CH, Mirakhur, B, Chan, E, Le, QT, Berlin, J, Morse, M, Murphy, BA, Satinover, SM, Hosen, J, Mauro, D, Slebos, RJ, Zhou, Q, Gold, D, Hatley, T, Hicklin, DJ, Platts-Mills, TA Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med, 358(11), 1109-17, 2008.
• Slebos, RJ, Brock, JW, Winters, NF, Stuart, SR, Martinez, MA, Li, M, Chambers, MC, Zimmerman, LJ, Ham, AJ, Tabb, DL, Liebler, DC Evaluation of strong cation exchange versus isoelectric focusing of peptides for multidimensional liquid chromatography-tandem mass spectrometry. J Proteome Res, 7(12), 5286-94, 2008.
• Luo, W, Slebos, RJ, Hill, S, Li, M, Brábek, J, Amanchy, R, Chaerkady, R, Pandey, A, Ham, AJ, Hanks, SK Global impact of oncogenic Src on a phosphotyrosine proteome. J Proteome Res, 7(8), 3447-60, 2008.
• Slebos, RJ, Li, M, Vadivelu, S, Burkey, BB, Netterville, JL, Sinard, R, Gilbert, J, Murphy, B, Chung, CH, Shyr, Y, Yarbrough, WG Microsatellite mutations in buccal cells are associated with aging and head and neck carcinoma. Br J Cancer, 98(3), 619-26, 2008.
• Palka, KT, Slebos, RJ, Chung, CH Update on molecular diagnostic tests in head and neck cancer. Semin Oncol, 35(3), 198-210, 2008.
• Flake, GP, Rivera, MP, Funkhouser, WK, Maygarden, SJ, Meadows, KL, Long, EH, Stockton, PS, Jones, TC, Yim, HW, Slebos, RJ, Taylor, JA Detection of Pre-Invasive Lung Cancer: Technical Aspects of the LIFE Project. Toxicol Pathol, 35(1), 65-74, 2007.
• Yarbrough, WG, Whigham, A, Brown, B, Roach, M, Slebos, R Phosphoinositide kinase-3 status associated with presence or absence of human papillomavirus in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys, 69(2 Suppl), S98-101, 2007.
• Yim, HW, Slebos, RJ, Randell, SH, Umbach, DM, Parsons, AM, Rivera, MP, Detterbeck, FC, Taylor, JA Smoking is associated with increased telomerase activity in short-term cultures of human bronchial epithelial cells. Cancer Lett, 246(1-2), 24-33, 2007.
• Chung, CH, Parker, JS, Ely, K, Carter, J, Yi, Y, Murphy, BA, Ang, KK, El-Naggar, AK, Zanation, AM, Cmelak, AJ, Levy, S, Slebos, RJ, Yarbrough, WG Gene Expression Profiles Identify Epithelial-to-Mesenchymal Transition and Activation of Nuclear Factor-{kappa}B Signaling as Characteristics of a High-risk Head and Neck Squamous Cell Carcinoma. Cancer Res, 66(16), 8210-8218, 2006.
• Slebos, RJ, Yi, Y, Ely, K, Carter, J, Evjen, A, Zhang, X, Shyr, Y, Murphy, BM, Cmelak, AJ, Burkey, BB, Netterville, JL, Levy, S, Yarbrough, WG, Chung, CH Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res, 12(3 Pt 1), 701-9, 2006.
• Chung, CH, Ely, K, McGavran, L, Varella-Garcia, M, Parker, J, Parker, N, Jarrett, C, Carter, J, Murphy, BA, Netterville, J, Burkey, BB, Sinard, R, Cmelak, A, Levy, S, Yarbrough, WG, Slebos, RJ, Hirsch, FR Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol, 24(25), 4170-6, 2006.
• Slebos, RJ, Li, M, Evjen, AN, Coffa, J, Shyr, Y, Yarbrough, WG Mutagenic effect of cadmium on tetranucleotide repeats in human cells. Mutat Res, 602(1-2), 92-9, 2006.
• Yarbrough, WG, Slebos, RJ, Liebler, D Proteomics: clinical applications for head and neck squamous cell carcinoma. Head Neck, 28(6), 549-58, 2006.
• Slebos, RJ, Livanos, E, Yim, HW, Randell, SH, Parsons, AM, Detterbeck, FC, Rivera, MP, Taylor, JA Chromosomal abnormalities in bronchial epithelium from smokers, nonsmokers, and lung cancer patients. Cancer Genet Cytogenet, 159(2), 137-42, 2005.
• Slebos, Robbert J C, Umbach, David M, Sommer, Courtney A, Horner, Geoffrey A, Choi, Jane Y, Taylor, Jack A Analytical and statistical methods to evaluate microsatellite allelic imbalance in small amounts of DNA. Lab Invest, 2004.
• Slebos, RJ, Little, RE, Umbach, DM, Antipkin, Y, Zadaorozhnaja, TD, Mendel, NA, Sommer, CA, Conway, K, Parrish, E, Gulino, S, Taylor, JA Mini-and microsatellite mutations in children from Chernobyl accident cleanup workers. Mutat Res, 559(1-2), 143-51, 2004.
• Jin, Yong Hwan, Clark, Alan B, Slebos, Robbert J C, Al-Refai, Hanan, Taylor, Jack A, Kunkel, Thomas A, Resnick, Michael A, Gordenin, Dmitry A, Cadmium is a mutagen that acts by inhibiting mismatch repair. Nat Genet, 34326-9, 2003.
• Slebos, Robbert J C, Oh, Daniel S, Umbach, David M, Taylor, Jack A, Mutations in tetranucleotide repeats following DNA damage depend on repeat sequence and carcinogenic agent. Cancer Res, 626052-60, 2002.
• Slebos, R J, Taylor, J A, A novel host cell reactivation assay to assess homologous recombination capacity in human cancer cell lines. Biochem Biophys Res Commun, 281212-9, 2001.
• Slebos, R J, Hoppin, J A, Tolbert, P E, Holly, E A, Brock, J W, Zhang, R H, Bracci, P M, Foley, J, Stockton, P, McGregor, L M, Flake, G P, Taylor, J A, K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study. Cancer Epidemiol Biomarkers Prev, 91223-32, 2000.
• Lax, S F, Kendall, B, Tashiro, H, Slebos, R J, Hedrick, L The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways.. Cancer, 88(4), 814-24, 2000.
• Slebos, R J, Resnick, M A, Taylor, J A Inactivation of the p53 tumor suppressor gene via a novel Alu rearrangement.. Cancer Res, 58(23), 5333-6, 1998.
• Wilentz, R E, Chung, C H, Sturm, P D, Musler, A, Sohn, T A, Offerhaus, G J, Yeo, C J, Hruban, R H, Slebos, R J K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma.. Cancer, 82(1), 96-103, 1998.
• Ceha, H M, Clement, M J, Polak, M M, Offerhaus, G J, Slebos, R J Mutational analysis of the P16-binding domain of cyclin-dependent kinase 4 in tumors in the head region of the pancreas.. Pancreas, 17(1), 85-8, 1998.
• Ceha, H M, Nasser, I, Medema, R H, Slebos, R J Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein.. Biochem Biophys Res Commun, 249(2), 550-5, 1998.
• Slebos, R J, Baas, I O, Clement, M J, Offerhaus, G J, Askin, F B, Hruban, R H, Westra, W H p53 alterations in atypical alveolar hyperplasia of the human lung.. Hum Pathol, 29(8), 801-8, 1998.
• Hruban, R H, Sturm, P D, Slebos, R J, Wilentz, R E, Musler, A R, Yeo, C J, Sohn, T A, van Velthuysen, M L, Offerhaus, G J Can K-ras codon 12 mutations be used to distinguish benign bile duct proliferations from metastases in the liver? A molecular analysis of 101 liver lesions from 93 patients.. Am J Pathol, 151(4), 943-9, 1997.
• Dijkhuizen, S M, Entius, M M, Clement, M J, Polak, M M, Van den Berg, F M, Craanen, M E, Slebos, R J, Offerhaus, G J Multiple hyperplastic polyps in the stomach: evidence for clonality and neoplastic potential.. Gastroenterology, 112(2), 561-6, 1997.
• Rodenhuis, S, Boerrigter, L, Top, B, Slebos, R J, Mooi, W J, van't Veer, L, van Zandwijk, N Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.. J Clin Oncol, 15(1), 285-91, 1997.
• Entius, M M, Westerman, A M, Giardiello, F M, van Velthuysen, M L, Polak, M M, Slebos, R J, Wilson, J H, Hamilton, S R, Offerhaus, G J Peutz-Jeghers polyps, dysplasia, and K-ras codon 12 mutations.. Gut, 41(3), 320-2, 1997.
• Slebos, R J, Baas, I O, Clement, M, Polak, M, Mulder, J W, van den Berg, F M, Hamilton, S R, Offerhaus, G J Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma.. Br J Cancer, 74(2), 165-71, 1996.
• Chung, C H, Wilentz, R E, Polak, M M, Ramsoekh, T B, Noorduyn, L A, Gouma, D J, Huibregtse, K, Offerhaus, G J, Slebos, R J Clinical significance of K-ras oncogene activation in ampullary neoplasms.. J Clin Pathol, 49(6), 460-4, 1996.
• Westra, W H, Baas, I O, Hruban, R H, Askin, F B, Wilson, K, Offerhaus, G J, Slebos, R J K-ras oncogene activation in atypical alveolar hyperplasias of the human lung.. Cancer Res, 56(9), 2224-8, 1996.
• Baas, I O, van den Berg, F M, Mulder, J W, Clement, M J, Slebos, R J, Hamilton, S R, Offerhaus, G J Potential false-positive results with antigen enhancement for immunohistochemistry of the p53 gene product in colorectal neoplasms.. J Pathol, 178(3), 264-7, 1996.
• Slebos, R J, Kessis, T D, Chen, A W, Han, S M, Hedrick, L, Cho, K R, Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro. Virology, 208111-20, 1995.
• Offerhaus, G J, Slebos, R J [Molecular-genetic detection of colorectal carcinoma in the feces]. Ned Tijdschr Geneeskd, 139(52), 2714-5, 1995.
• Kern, J A, Slebos, R J, Top, B, Rodenhuis, S, Lager, D, Robinson, R A, Weiner, D, Schwartz, D A C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.. J Clin Invest, 93(2), 516-20, 1994.
• Slebos, R J, Lee, M H, Plunkett, B S, Kessis, T D, Williams, B O, Jacks, T, Hedrick, L, Kastan, M B, Cho, K R p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein.. Proc Natl Acad Sci U S A, 91(12), 5320-4, 1994.
• Kessis, T D, Slebos, R J, Nelson, W G, Kastan, M B, Plunkett, B S, Han, S M, Lorincz, A T, Hedrick, L, Cho, K R Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage.. Proc Natl Acad Sci U S A, 90(9), 3988-92, 1993.
• Westra, W H, Slebos, R J, Offerhaus, G J, Goodman, S N, Evers, S G, Kensler, T W, Askin, F B, Rodenhuis, S, Hruban, R H K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung.. Cancer, 72(2), 432-8, 1993.
• Slichenmyer, W J, Nelson, W G, Slebos, R J, Kastan, M B Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage.. Cancer Res, 53(18), 4164-8, 1993.
• Westra, W H, Offerhaus, G J, Goodman, S N, Slebos, R J, Polak, M, Baas, I O, Rodenhuis, S, Hruban, R H Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking.. Am J Surg Pathol, 17(3), 213-20, 1993.
• Kessis, T D, Slebos, R J, Han, S M, Shah, K, Bosch, X F, Muñoz, N, Hedrick, L, Cho, K R p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix.. Am J Pathol, 143(5), 1398-405, 1993.
• Slebos, R J, Boerrigter, L, Evers, S G, Wisman, P, Mooi, W J, Rodenhuis, S A rapid and simple procedure for the routine detection of ras point mutations in formalin-fixed, paraffin-embedded tissues.. Diagn Mol Pathol, 1(2), 136-41, 1992.
• Rodenhuis, S, Slebos, R J Clinical significance of ras oncogene activation in human lung cancer.. Cancer Res, 52(9 Suppl), 2665s-2669s, 1992.
• Slebos, R J, Rodenhuis, S The ras gene family in human non-small-cell lung cancer.. J Natl Cancer Inst Monogr, (13), 23-9, 1992.
• Slebos, R J, Habets, G G, Evers, S G, Mooi, W J, Rodenhuis, S Allele-specific detection of K-ras oncogene expression in human non-small-cell lung carcinomas.. Int J Cancer, 48(1), 51-6, 1991.
• Breuer, M, Wientjens, E, Verbeek, S, Slebos, R, Berns, A Carcinogen-induced lymphomagenesis in pim-1 transgenic mice: dose dependence and involvement of myc and ras. Cancer Res, 51(3), 958-63, 1991.
• Oudejans, J J, Slebos, R J, Zoetmulder, F A, Mooi, W J, Rodenhuis, S Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver.. Int J Cancer, 49(6), 875-9, 1991.
• Rygaard, K, Slebos, R J, Spang-Thomsen, M Radiosensitivity of small-cell lung cancer xenografts compared with activity of c-myc, N-myc, L-myc, c-raf-1 and K-ras proto-oncogenes.. Int J Cancer, 49(2), 279-84, 1991.
• Slebos, R J, Hruban, R H, Dalesio, O, Mooi, W J, Offerhaus, G J, Rodenhuis, S Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung.. J Natl Cancer Inst, 83(14), 1024-7, 1991.
• Slebos, R J, Kibbelaar, R E, Dalesio, O, Kooistra, A, Stam, J, Meijer, C J, Wagenaar, S S, Vanderschueren, R G, van Zandwijk, N, Mooi, W J K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung.. N Engl J Med, 323(9), 561-5, 1990.
• Rodenhuis, S, Slebos, R J The ras oncogenes in human lung cancer.. Am Rev Respir Dis, 142(6 Pt 2), S27-30, 1990.
• Slebos, R J, Evers, S G, Wagenaar, S S, Rodenhuis, S Cellular protoonocogenes are infrequently amplified in untreated non-small cell lung cancer.. Br J Cancer, 59(1), 76-80, 1989.
• Slebos, R J, Rodenhuis, S The molecular genetics of human lung cancer.. Eur Respir J, 2(5), 461-9, 1989.
• Breuer, M, Slebos, R, Verbeek, S, van Lohuizen, M, Wientjens, E, Berns, A Very high frequency of lymphoma induction by a chemical carcinogen in pim-1 transgenic mice. Nature, 340(6228), 61-3, 1989.
• Höppener, J W, Mosselman, S, Roholl, P J, Lambrechts, C, Slebos, R J, de Pagter-Holthuizen, P, Lips, C J, Jansz, H S, Sussenbach, J S Expression of insulin-like growth factor-I and -II genes in human smooth muscle tumours.. EMBO J, 7(5), 1379-85, 1988.
• Rodenhuis, S, Slebos, R J, Boot, A J, Evers, S G, Mooi, W J, Wagenaar, S S, van Bodegom, P C, Bos, J L Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung.. Cancer Res, 48(20), 5738-41, 1988.
• Slebos, R J, de Graeff, A, Van Zandwijk, N, Mooi, W J, Bos, J L, Rodenhuis, S Recurrent breast cancer and an adenocarcinoma of the lung occurring in one patient: c-myc oncogene amplification and K-ras codon 12 point mutation as tumour markers.. Eur J Cancer Clin Oncol, 24(9), 1529-30, 1988.
• de Graeff, A, Slebos, R J, Rodenhuis, S Resistance to cisplatin and analogues: mechanisms and potential clinical implications.. Cancer Chemother Pharmacol, 22(4), 325-32, 1988.
• Höppener, J W, Steenbergh, P H, Slebos, R J, de Pagter-Holthuizen, P, Roos, B A, Jansen, M, Van den Brande, J L, Sussenbach, J S, Jansz, H S, Lips, C J Expression of insulin-like growth factor-I and -II genes in rat medullary thyroid carcinoma.. FEBS Lett, 215(1), 122-6, 1987.
• Höppener, J W, Steenbergh, P H, Slebos, R J, Visser, A, Lips, C J, Jansz, H S, Bechet, J M, Lenoir, G M, Born, W, Haller-Brem, S Expression of the second calcitonin/calcitonin gene-related peptide gene in Ewing sarcoma cell lines.. J Clin Endocrinol Metab, 64(4), 809-17, 1987.

Education

• Ph.D. in Molecular Biology, University of Amsterdam, Netherlands, 1991
• M.H.S. in Clinical Research, Duke University, Durham NC, 2003